Continuation of the Levonorgestrel-Releasing Intrauterine Device Among Adolescents With Endometriosis
Journal of Pediatric and Adolescent Gynecology · 2025-02 · 38 (1) · 85-88
DOI: 10.1016/j.jpag.2024.10.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pediatric and Adolescent Gynecology, 2025-02. Verfasst von Jessica Y Shim und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gynecology, Boston Children's Hospital, Boston, Massachusetts. Electronic address: Jessica.shim@childrens.harvard.edu. Hauptthemen laut MEDLINE: Endometriosis, Levonorgestrel, Intrauterine Devices, Medicated, Contraceptive Agents, Female. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
STUDY OBJECTIVE: To estimate the 1-year continuation rate of the levonorgestrel-releasing intrauterine device (LNG-IUD) in adolescents with endometriosis, and the frequency at which additional systemic hormonal treatment (HT) is utilized. METHODS: A retrospective cohort study was performed of patients aged 12-21 years who underwent laparoscopy for endometriosis and LNG-IUD insertion at a single tertiary care institution between 2018 and 2021. RESULTS: We evaluated 224 adolescents (mean age = 17.0, SD = 1.8 years) who underwent LNG-IUD placement during laparoscopic evaluation for endometriosis. Stage I endometriosis was most common (84.4%), followed by stage II (13.0%). Of 221 with follow-up, 208 (94.1%) had HT added or continued postsurgery. The most common additional HT was norethindrone acetate (42.5%), followed by combined hormonal contraceptives (34.8%). The 1-year LNG-IUD continuation rate was 92.0%. There were 18 IUD removals (8%) by 1 year, and the median time to removal was 118 days (interquartile range = 159; range 8-293). Use of additional HT was associated with a lower hazard of IUD removal within the first year of use (hazard ratio = 0.19, 95% confidence interval: 0.06-0.56, P < .001). CONCLUSION: The majority of adolescents used the LNG-IUD with additional systemic HT for endometriosis management. While overall continuation was high, adolescents who were using LNG-IUD and HT were more likely to continue LNG-IUD than those who were not utilizing additional HT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gynecology, Boston Children's Hospital, Boston, Massachusetts. Electronic address: Jessica.shim@childrens.harvard.edu.
- Institutional Centers for Clinical and Translational Research, Boston Children's Hospital, Boston, Massachusetts.
- Division of Adolescent/Young Adult Medicine, Boston Children's Hospital, Boston, Massachusetts.
Zitieren
APA
Shim, J. Y., Milliren, C. E., & DiVasta, A. D. (2025). Continuation of the Levonorgestrel-Releasing Intrauterine Device Among Adolescents With Endometriosis. Journal of Pediatric and Adolescent Gynecology, 38(1), 85-88. https://doi.org/10.1016/j.jpag.2024.10.005
Vancouver
Shim JY, Milliren CE, DiVasta AD. Continuation of the Levonorgestrel-Releasing Intrauterine Device Among Adolescents With Endometriosis. Journal of Pediatric and Adolescent Gynecology. 2025;38(1):85-88. doi:10.1016/j.jpag.2024.10.005
BibTeX
@article{Shim2025,
author = {Shim, Jessica Y and Milliren, Carly E and DiVasta, Amy D},
title = {Continuation of the Levonorgestrel-Releasing Intrauterine Device Among Adolescents With Endometriosis},
journal = {Journal of Pediatric and Adolescent Gynecology},
year = {2025},
volume = {38},
number = {1},
pages = {85--88},
doi = {10.1016/j.jpag.2024.10.005}
}
EUVIMED